Trials / Completed
CompletedNCT02818465
Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients
Role of the Interaction Between AGEs and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- CHU de Reims · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chronic kidney disease (CKD) is associated with an extensive vasculopathy and high cardiovascular mortality as well as an accumulation of uremic toxins. Among the latest, advanced glycation end-products (AGEs) interact with RAGE. Investigators aimed to analyze the role of RAGE in the calcification process of hemodialyzed patients, in a correlative and prospective study. Vascular calcifications will be assessed by Xray and tomodentimetry while accumulation of AGEs will be measured in the serum and in the skin (non invasive). Additionally factors influencing RAGE activation such as genetic polymorphism and level of soluble forms of RAGE will be measured and analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Vascular calcifications by Xray | |
| OTHER | Vascular calcifications by tomodentimetry | |
| BIOLOGICAL | Blood sample withdrawn |
Timeline
- Start date
- 2015-03-30
- Primary completion
- 2017-11-16
- Completion
- 2017-11-16
- First posted
- 2016-06-29
- Last updated
- 2026-01-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02818465. Inclusion in this directory is not an endorsement.